US FDA Begins Implementing New User Fee Programs, But What About The Actual Fees?
Executive Summary
Sponsors looking to file applications continue to wait for the new user fees to be announced, as details of the Split Real-Time Application Review (STAR) program, generic drug facility inspection readiness requirement and other changes are revealed.
You may also be interested in...
Real-Time Oncology Review Excludes Applications Needing Adcomms Or New REMS
Applications no longer need to have ‘straightforward study designs’ to qualify for RTOR, but no aspect of the submission should be likely to require a longer review time, US FDA says in a final guidance on the expedited pathway.
US FDA’s Oncology Divisions Have Been Providing Live Meeting Minutes For Years. Will Others Follow?
Oncology division officials summarize the agreements and discussions reached during formal meetings so there are no misunderstandings later. Sponsors want the practice used more widely by the FDA.
US FDA Doesn’t Want ANDAs With Facilities Not Ready For Inspection Even Though It Can Accept Them
An agency official said the GDUFA III provision hopefully will be used for only a small number of ANDAs. We chart the approval times and first-cycle clearances over the course of the generic user fee program.